100-Unit Sterile Fill-Finish
Robotics Program.
This companion page summarizes the Letter of Intent between United Therapeutics Corporation and Engage Work LLC: a staged robotics program for sterile fill-finish operations — from discovery and engineering feasibility through pilot deployment, design freeze, and scale-up toward a 100-unit production fleet, with Engage as prime commercial and integration counterparty.
The environment, on film.
01 · FIELD FOOTAGEReal footage from program field work: a humanoid platform performing an intervention at a stainless pass-through, and the cleanroom isolator environment the fleet is engineered to serve.
The platform: G2.
02 · REFERENCE PLATFORMThe program's reference platform is the G2 wheeled industrial humanoid — force-controlled arms on a stable omnidirectional base — re-engineered to the Grade A conditions set out in Annex A. Its baseline capabilities map directly onto the critical-zone tasks this program contemplates.
| G2 BASELINE | WHY IT MATTERS IN THE GRADE A ZONE |
|---|---|
| 7-DOF FORCE-CONTROLLED ARMS | Bounded, repeatable force on fragile primary packaging — vials, stoppers, crimp caps — per Annex A.2. |
| 2× 360° VISION COVERAGE | Component identification, pose estimation and verification of intervention outcomes. |
| 122.5–179.5 CM ADJUSTABLE HEIGHT | Reaches isolator gloveports, RABS openings and pass-through hatches without repositioning fixed automation. |
| STABLE WHEELED BASE · 185 KG | Deterministic, vibration-controlled motion between suites — one validated platform across intervention types (Annex A.5). |
| 4+ HR RUNTIME · 26+ DOF | Multi-intervention shifts inside the sterile envelope without operator entry — the program's core contamination-control rationale. |
Six phases to a fleet.
03 · PROGRAM STRUCTURE| PHASE | SCOPE | PLANNING DURATION | PAYMENT (USD) | % |
|---|---|---|---|---|
| P0 | Discovery & Architecture | 6–8 weeks | 3,975,608 | 10% |
| P1 | Engineering Feasibility | 12–16 weeks | 3,975,608 | 10% |
| P2 | Production-Intent Engineering | 16–24 weeks | 3,975,608 | 10% |
| P3 | Pilot Build, FAT & Site Deployment | 24–32 weeks | 5,963,412 | 15% |
| P4 | Pilot Evidence & Design Freeze | 6–12 months | 5,963,412 | 15% |
| P5 | Production Scale-Up / Full Deployment | 12–18 months | 15,902,432 | 40% |
| Total contemplated program value | 39,756,080 | 100% |
Planning durations are indicative and may overlap where technically appropriate. Payment triggers, invoicing mechanics, acceptance criteria, dependencies and phase-specific deliverables will be set out in the definitive agreement and/or applicable statements of work.
Engineered for the Grade A zone.
04 · TECHNICAL & REGULATORY BASISAnnex A of the LOI sets out the conditions the program is engineered to satisfy — summarized here in the terms that matter to a regulated manufacturing operation.
Grade A / ISO Class 5, by design
Non-porous, electropolished surfaces surviving repeated VHP decontamination; sealed drive units with effectively zero particle output; washdown-rated construction; motion profiles that respect unidirectional laminar airflow over the critical zone.
Task-specific, not general-purpose
Non-shedding fine-motor grippers for glass vials, stoppers, crimp caps and syringes; high-accuracy 3D vision for component identification and verification; force and tactile feedback bounding applied load on fragile components.
Qualified before routine use
EU GMP Annex 1 and applicable FDA requirements; IQ / OQ / PQ against agreed acceptance criteria; dynamic airflow studies with the platform in motion; CSV across controls and audit trail; contamination risk assessment supported by media fills.
Interventions, not filling lines
Fixed cleanroom automation keeps doing what it does best. The humanoid form factor covers the flexible interventions that would otherwise require a human to breach the sterile envelope — clearing jammed stoppers, replacing liquid lines, handling environmental monitoring plates — one validated platform across the suite.
Nature of this document: this page and the linked LOI record a statement of present commercial intent and a framework for preparation of definitive agreements. Except for any provisions expressly stated to be binding in a subsequently executed version, neither obligates either party to complete the contemplated transaction or program until definitive agreements are executed by authorized representatives of both parties. Figures shown are the contemplated values from the LOI dated August 21, 2026 and remain subject to final technical definition, acceptance criteria and definitive agreements.